Suppr超能文献

喹吖因对血管加压素诱导的离体肝细胞中糖原磷酸化酶活性、Ca2+转运及磷酸肌醇代谢变化的影响。

Effects of quinacrine on vasopressin-induced changes in glycogen phosphorylase activity, Ca2+ transport and phosphoinositide metabolism in isolated hepatocytes.

作者信息

Barritt G J, Milton S E, Hughes B P

机构信息

Department of Medical Biochemistry, Flinders University School of Medicine, Bedford Park, South Australia.

出版信息

Biochem Pharmacol. 1988 Jan 15;37(2):161-7. doi: 10.1016/0006-2952(88)90713-7.

Abstract

In isolated hepatocytes, quinacrine (150-250 microM) inhibited vasopressin-induced increases in glucose release, glycogen phosphorylase a activity and 45Ca2+ efflux; and glucagon-induced increases in glucose release and cyclic AMP formation. These results indicate that a phospholipase A2 enzyme sensitive to quinacrine is unlikely to be involved in the process by which vasopressin stimulates glycogen phosphorylase activity in the liver cell. In cells labelled with [3H]inositol, much lower concentrations of quinacrine (20-50 microM) inhibited the stimulation by vasopressin of the accumulation of [3H]inositol. The drug had little effect on vasopressin-induced accumulation of [3H]inositol mono-, bis- and tris-phosphates. In the absence of vasopressin, higher concentrations of quinacrine caused a small stimulation of glycogen phosphorylase activity, 45Ca2+ release and the formation of [3H]inositol polyphosphates. Quinacrine did not inhibit the degradation by liver homogenates of inositol 1-phosphate, inositol 4,5-bisphosphate or inositol 1,4,5-trisphosphate. It is concluded that concentrations of quinacrine comparable with those which inhibit phospholipase A2 [G.J. Blackwell, W.G. Duncombe, R.J. Flower, M.F. Parsons and J.R. Vane, Br. J. Pharmac. 59, 353-366 (1977)] inhibit the stimulation by vasopressin of inositol utilization without significantly affecting coupling between hormone receptors and adenyl cyclase or phosphoinositide-specific phosphodiesterase, the action of the phosphodiesterase, and the degradation of inositol triphosphate.

摘要

在分离的肝细胞中,奎纳克林(150 - 250微摩尔)抑制血管加压素诱导的葡萄糖释放增加、糖原磷酸化酶a活性增加以及45Ca2+外流;并抑制胰高血糖素诱导的葡萄糖释放增加和环磷酸腺苷生成。这些结果表明,对奎纳克林敏感的磷脂酶A2不太可能参与血管加压素刺激肝细胞中糖原磷酸化酶活性的过程。在用[3H]肌醇标记的细胞中,浓度低得多的奎纳克林(20 - 50微摩尔)抑制血管加压素对[3H]肌醇积累的刺激作用。该药物对血管加压素诱导的[3H]肌醇单磷酸、双磷酸和三磷酸积累影响很小。在没有血管加压素的情况下,较高浓度的奎纳克林会引起糖原磷酸化酶活性、45Ca2+释放以及[3H]肌醇多磷酸生成的轻微刺激。奎纳克林不抑制肝匀浆对肌醇1 - 磷酸、肌醇4,5 - 双磷酸或肌醇1,4,5 - 三磷酸的降解。结论是,与抑制磷脂酶A2的浓度相当的奎纳克林浓度[G.J.布莱克韦尔、W.G.邓科姆、R.J.弗劳尔、M.F.帕森斯和J.R.瓦恩,《英国药理学杂志》59,353 - 366(1977)]抑制血管加压素对肌醇利用的刺激,而不会显著影响激素受体与腺苷酸环化酶或磷酸肌醇特异性磷酸二酯酶之间的偶联、磷酸二酯酶的作用以及肌醇三磷酸的降解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验